Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
- Conditions
- Refractory Acute Myeloid LeukemiaMyeloid NeoplasmRecurrent Acute Myeloid Leukemia
- Interventions
- Biological: Recombinant Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 13
- Registration Number
- NCT04196010
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Medium Dose of Cytarabine and Mitoxantrone
- Conditions
- ChemotherapyAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT04024241
- Locations
- 🇨🇳
Shenzhen, Shenzhen, Guangdong, China
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Echocardiogram RecordingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03983824
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
University of California, Irvine, California, United States
🇺🇸Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT03860844
- Locations
- 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Robert Redner, MD
- Target Recruit Count
- 16
- Registration Number
- NCT03839446
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma
- Conditions
- Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT03776279
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03735446
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- Conditions
- FLT3-mutated Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03591510
- Locations
- 🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States
🇺🇸Miami Children s Hospital, Miami, Florida, United States
🇹🇷Novartis Investigative Site, Istanbul, Turkey
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03563560
- Locations
- 🇯🇵
Fukui University Hospital, Yoshida-gun, Fukui, Japan
🇯🇵Chugoku Central Hospital, Fukuyama, Hiroshima, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.